Skip to main
CARL

Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed Inc (CARL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Carlsmed is a promising investment with a Buy rating and a projected price target of $17. Their AI platform for personalized spine fusions has resulted in lower revision rates and favorable reimbursement, which has led to increased surgeon adoption and revenue growth. While there are potential risks in the competitive market and operational and reimbursement challenges, the company has a strong patent portfolio, leadership team, and potential for further growth with their cervical platform and changes in the IPPS proposal.

Bears say

Carlsmed is currently unprofitable and there is a lack of transparency in terms of when cash flow breakeven can be reached. While the AI-enabled personalized solutions provided by the Aprevo technology platform may differentiate the company from traditional implants, the potential for pricing pressure and reimbursement changes could affect future revenue growth and dampen profitability. Additionally, the company's limited track record and reliance on a small customer base of surgeons may pose risks to its growth and market penetration potential.

Carlsmed Inc (CARL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Carlsmed Inc (CARL) Forecast

Analysts have given Carlsmed Inc (CARL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Carlsmed Inc (CARL) has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Carlsmed Inc (CARL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.